

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM420329

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Agena Bioscience, Inc.		03/17/2017	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	MidCap Financial Trust		
<b>Street Address:</b>	c/o MidCap Financial Services, LLC, as servicer		
<b>Internal Address:</b>	7255 Woodmont Avenue, Suite 200		
<b>City:</b>	Bethesda		
<b>State/Country:</b>	MARYLAND		
<b>Postal Code:</b>	20814		
<b>Entity Type:</b>	Statutory Trust: DELAWARE		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3363895	EPITYPER	
<b>Registration Number:</b>	3228569	IPLEX	
<b>Registration Number:</b>	4031877	ISEQ	
<b>Registration Number:</b>	2878299	MASSARRAY	
<b>Registration Number:</b>	2767429	MASSEXTEND	
<b>Registration Number:</b>	2602034	SPECTROCHIP	
<b>Registration Number:</b>	4733377	HEMO ID	
<b>Registration Number:</b>	4633026	LUNGCARTA	
<b>Serial Number:</b>	86309704	AGENA BIOSCIENCE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4044435697		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	212-548-7083		
<b>Email:</b>	lallen@mcguirewoods.com		
<b>Correspondent Name:</b>	Richard C. Tisdale, Esq.		
<b>Address Line 1:</b>	McGuireWoods LLP		
<b>Address Line 2:</b>	1230 Peachtree Street, N.E., Suite 2100		
<b>Address Line 4:</b>	Atlanta, GEORGIA 30309		

OP \$240.00 3363895

TRADEMARK

<b>ATTORNEY DOCKET NUMBER:</b>	2061695-0035 Agena
<b>NAME OF SUBMITTER:</b>	Latosha E. Allen
<b>SIGNATURE:</b>	/Latosha E. Allen/
<b>DATE SIGNED:</b>	03/20/2017

**Total Attachments: 16**

source=Agena - Intellectual Property Security Agreemen#page1.tif  
source=Agena - Intellectual Property Security Agreemen#page2.tif  
source=Agena - Intellectual Property Security Agreemen#page3.tif  
source=Agena - Intellectual Property Security Agreemen#page4.tif  
source=Agena - Intellectual Property Security Agreemen#page5.tif  
source=Agena - Intellectual Property Security Agreemen#page6.tif  
source=Agena - Intellectual Property Security Agreemen#page7.tif  
source=Agena - Intellectual Property Security Agreemen#page8.tif  
source=Agena - Intellectual Property Security Agreemen#page9.tif  
source=Agena - Intellectual Property Security Agreemen#page10.tif  
source=Agena - Intellectual Property Security Agreemen#page11.tif  
source=Agena - Intellectual Property Security Agreemen#page12.tif  
source=Agena - Intellectual Property Security Agreemen#page13.tif  
source=Agena - Intellectual Property Security Agreemen#page14.tif  
source=Agena - Intellectual Property Security Agreemen#page15.tif  
source=Agena - Intellectual Property Security Agreemen#page16.tif

**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This Intellectual Property Security Agreement is entered into as of the 17th day of March, 2017 by and among **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), **AGENA BIOSCIENCE, INC.**, a Delaware corporation (the “**Grantor**”).

**RECITALS**

A. The Lenders (as defined below) have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Credit Extensions**”) in the amounts and manner set forth in that certain Credit and Security Agreement by and among Agent, the financial institutions party thereto from time to time (collectively, the “**Lenders**”), and Grantor, dated as of March 17, 2017 (as the same may be amended, modified or supplemented from time to time, the “**Credit Agreement**”; capitalized terms used herein are used as defined in the Credit Agreement). The Lenders are willing to make the Credit Extensions to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Credit Agreement.

B. Pursuant to the terms of the Credit Agreement, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as specifically defined in the Credit Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

**AGREEMENT**

To secure its obligations under the Credit Agreement, each Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of such Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to such Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Credit Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Credit Agreement and the other Financing Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Credit Agreement or any of the Financing Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Credit Agreement or any of the other Financing Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

*[Remainder of page intentionally blank; signature page follows.]*


**IN WITNESS WHEREOF**, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

Address of Grantor:

Agena Bioscience, Inc.  
4755 Eastgate Mall  
San Diego, CA 92121  
Attention: Terry Kinninger, CFO  
E-Mail: Terry.Kinninger@agenabio.com

**AGENA BIOSCIENCE, INC.**

  
\_\_\_\_\_  
Terry Kinninger (SEAL)  
Chief Financial Officer

AGENT:

MIDCAP FINANCIAL TRUST

Address of Agent:

MidCap Financial Trust  
c/o MidCap Financial Services, LLC, as servicer  
7255 Woodmont Ave, Suite 200  
Bethesda, MD 20814  
Attn: Account Manager for Agena transaction  
Facsimile: 301-941-1450  
Email: notices@midcapfinancial.com

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:  (SEAL)  
Name: Maurice Amsellem  
Title: Authorized Signatory

EXHIBIT A

Copyrights

NONE.

EXHIBIT B

Patents

SEE ATTACHED.



Reference No.	PATENT OR PATENT APPLICATION TITLE	Application Type/No. Country	Patent or Publication Number	Filing Date	Status
1.	<b>SEQ-2001</b>				
2.	Systems and Methods for Preparing and Analyzing Low Volume Analyte Array Elements	CP	US6024925	1/23/97	Issued
3.	Systems and Methods for Preparing and Analyzing Low Volume Analyte Array Elements	UT2	US7285422	1/23/97	Issued
4.	Systems and Methods for Preparing and Analyzing Low Volume Analyte Array Elements	DV	US7232688	7/30/99	Issued
5.	Systems and Methods for Preparing and Analyzing Low Volume Analyte Array Elements	DV2	US6569385	10/28/99	Issued
6.	Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Substrates Having Low Volume Matrix Array Elements	CT	8821816	5/19/08	Issued
	<b>SEQ 2046</b>				
7.	Method and Apparatus for Delivery of Submicroliter Volumes onto a Substrate	CT2	8999266	11/21/12	Issued
	Method and Apparatus for Delivery of Submicroliter Volumes onto a Substrate	CT3	14656267	3/12/15	Pending
	<b>SEQ 2049</b>				
8.	Method and Device for Identifying a Biological Sample	UT	US7917301	9/19/00	Issued
9.	Method and Device for Identifying a Biological Sample	AU	AU776811B2	10/13/00	Issued
10.	Method and Device for Identifying a Biological Sample	DE	EP1350211	9/18/01	Issued
11.	Method and Device for Identifying a Biological Sample	FR	EP1350211	9/18/01	Issued
12.	Method and Device for Identifying a Biological Sample	GB	EP1350211	9/18/01	Issued
13.					
14.	Method and Device for Identifying a Biological Sample	IT	EP1350211	9/18/01	Issued
	<b>SEQ 2050</b>				
15.	System and Method for Testing a Biological Sample	CP	US8315805	4/22/02	Issued
16.	System and Method for Testing a Biological Sample	EP	EP1390900	4/22/02	Pending
	<b>SEQ 2066</b>				
17.	Methods of Making Substrates for Mass Spectrometry Analysis and Related Devices	UT	US7019288	9/29/04	Issued
	<b>SEQ 2073</b>				
18.	Fragmentation-based Methods and Systems for Sequence Variation Detection and Discovery	UT	US7820378	11/26/03	Issued
19.	Fragmentation-based Methods and Systems for Sequence Variation Detection and Discovery	AU	AU3298733B B	11/26/03	Issued
20.	Fragmentation-based Methods and Systems for Sequence Variation Detection and Discovery	CA	2507189	11/26/03	Pending
21.	Fragmentation-based Methods and Systems for Sequence Variation Detection and Discovery	CN	CN1774511B	11/26/03	Issued
22.	Fragmentation-based Methods and Systems for Sequence Variation Detection and Discovery	EP	EP1613723	11/26/03	Issued

Reference No.	PATENT OR PATENT APPLICATION TITLE	Application Type/No. Country	Patent or Publication Number	Filing Date	Status
23.	Fragmentation-based Methods and Systems for Sequence Variation Detection and Discovery	HK	1087436		Issued
24.					
25.	Fragmentation-based Methods and Systems for Sequence Variation Detection and Discovery	JP	4786904B2	11/26/03	Issued
	<b>SEQ 2079</b>				
26.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	EP	EP1660680B1	7/30/04	Issued
27.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	FR	EP1660680B1	7/30/04	Issued
28.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	DE	EP1660680B1	7/30/04	Issued
29.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	UK	EP1660680B1	7/30/04	Issued
30.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	UT	US8003317	7/30/04	Issued
31.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	CT	US8349566	7/28/11	Issued
32.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	CT2	9068223	12/18/12	Issued
33.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	CT3	14720179		Pending
34.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	GB	EP2107129B	3/10/09	Issued
35.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	DE	EP2107129B	3/10/09	Issued
36.	Methods for High Level Multiplexed Polymerase Chain Reactions and Homogeneous Mass Extension Reactions	IE	EP2107129B	3/10/09	Issued
	<b>SEQ 2080</b>				
37.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	AU	AU5230936B2	3/24/05	Issued
38.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	CA	CA2561381	3/24/05	Issued
39.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	DE	EP1727911B1	3/24/05	Issued

Reference No.	PATENT OR PATENT APPLICATION TITLE	Application Type/No. Country	Patent or Publication Number	Filing Date	Status
40.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	HK	1098792B	3/24/05	Issued
41.					
42.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	UT	9249456	3/24/05	Issued
43.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	EP2	EP2395098	3/24/05	Pending
44.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	FR	EP1727911B 1	3/24/05	Issued
45.	Base Specific Cleavage of Methylation-specific Amplification Products in Combination with Mass Analysis	GB	EP1727911B 1	3/24/05	Issued
	<b>SEQ 6015</b>				
46.	Methods For Reducing Adduct Formation For Mass Spectrometry Analysis	UT	US7,888,127	1/15/08	Issued
47.	Compositions and Processes for Improved Mass Spectrometry Analysis	CT	9310378	1/7/11	Issued
48.	Compositions and Processes for Improved Mass Spectrometry Analysis	AU	2009205404	1/14/09	Issued
49.	Compositions and Processes for Improved Mass Spectrometry Analysis	AU2	2014203336	1/14/09	Pending
50.	Compositions and Processes for Improved Mass Spectrometry Analysis	CA	2711943	1/14/09	Pending
51.	Compositions and Processes for Improved Mass Spectrometry Analysis	CN	101965221	1/14/09	Pending
52.	Compositions and Processes for Improved Mass Spectrometry Analysis	CN2	20161075300 27	1/14/09	Pending
53.	Compositions and Processes for Improved Mass Spectrometry Analysis	EA	017342B1	1/14/09	Issued
54.	Compositions and Processes for Improved Mass Spectrometry Analysis	EP	EP2242561	1/14/09	Issued
55.	Compositions and Processes for Improved Mass Spectrometry Analysis	EP2	161813001		Pending
56.	Compositions and Processes for Improved Mass Spectrometry Analysis	HK	WO20090918 41A2	4/20/11	Pending
57.	Compositions and Processes for Improved Mass Spectrometry Analysis	IN	WO20090918 41A2	1/14/09	Pending
58.	Compositions and Processes for Improved Mass Spectrometry Analysis	JP	5400799B1	1/14/09	Issued
59.	Compositions and Processes for Improved Mass Spectrometry Analysis	KR	WO20090918 41A2	1/14/09	Pending
60.	Compositions and Processes for Improved Mass Spectrometry Analysis	SG	163201	1/14/09	Issued
61.	Compositions and Processes for Improved Mass Spectrometry Analysis	JP2	5651842	1/14/09	Issued

Reference No.	PATENT OR PATENT APPLICATION TITLE	Application Type/No. Country	Patent or Publication Number	Filing Date	Status
	<b>SEQ 6020</b>				
62.	Products and processes for multiplex nucleic acid identification	US	20120046178	10/27/09	Pending
63.	Products and processes for multiplex nucleic acid identification	CA	2742272	10/27/09	Pending
64.	Products and processes for multiplex nucleic acid identification	EP	EP2356259	10/27/09	Pending
65.	Products and Processes for Multiplex Nucleic Acid Identification	CT2T	US20130017960	7/17/12	Pending
66.	Products and Processes for Multiplex Nucleic Acid Identification	CT3	US20140011195	3/8/13	Pending
67.	Products and Processes for Multiplex Nucleic Acid Identification	EP2	EP2710144	5/18/12	Pending
68.	Products and Processes for Multiplex Nucleic Acid Identification	JP	2014511601	5/18/12	Allowed
69.	Products and Processes for Multiplex Nucleic Acid Identification	JP2	201696686	5/18/12	Pending
70.	Products and Processes for Multiplex Nucleic Acid Identification	CN	2012-80035668.9	5/18/12	Pending
71.	Products and Processes for Multiplex Nucleic Acid Identification	CA2	2835942	5/18/12	Pending
72.	Products and Processes for Multiplex Nucleic Acid Identification	EA	201391723	5/18/12	Pending
73.	Products and Processes for Multiplex Nucleic Acid Identification	AU	2012254985	5/18/12	Pending
74.	Products and Processes for Multiplex Nucleic Acid Identification	DV	13/790996	3/8/13	Pending
75.	Products and Processes for Multiplex Nucleic Acid Identification	PC2	PCT/US2012/038710	5/18/12	Pending
	<b>SEQ 6061</b>				
76.	Preparation Enhancements And Methods Of Use For Maldi Mass Spectrometry	Ut	9305756	3/13/13	Issued
77.	Preparation Enhancements And Methods Of Use For Maldi Mass Spectrometry	CT	15/062,778	3/7/16	Pending
78.	Preparation Enhancements And Methods Of Use For Maldi Mass Spectrometry	PCT	PCT/US2014/020001	3/3/14	Pending
	Preparation Enhancements And Methods Of Use For Maldi Mass Spectrometry	AU	2014249722	3/3/14	Pending
	Preparation Enhancements And Methods Of Use For Maldi Mass Spectrometry	CA	2902323	3/3/14	Pending
	Preparation Enhancements And Methods Of Use For Maldi Mass Spectrometry	CN	2014800145672	3/3/14	Pending
	Preparation Enhancements And Methods Of Use For Maldi Mass Spectrometry	EP	147107619	3/3/14	Pending
	<b>RIGAKU ACQUIRED IP</b>				
79.	Microarray Dispensing with Real Time Verification and Inspection	US	6558623	5/6/03	Issued
80.	Microarray Dispensing with Real Time Verification	EP	EP1307291		Allowed

Reference No.	PATENT OR PATENT APPLICATION TITLE	Application Type/No. Country	Patent or Publication Number	Filing Date	Status
	and Inspection				
81.	Microarray Dispensing with Real Time Verification and Inspection	US	7025933	4/11/06	Issued
82.	Microarray Dispensing with Real Time Verification and Inspection	EP	EP1638689	7/21/10	Issued
	<b>7001</b>				
	Multiplexed Method for the Identification and Quantification of Minor Alleles and Polymorphisms	UT	15/136,024	4/22/16	Pending
	Multiplexed Method for the Identification and Quantification of Minor Alleles and Polymorphisms	PCT	PCT/US2016 028971	4/22/16	Pending
	<b>7002</b>				
	Multiplex Methods for the Detection and Quantification of Minor Variants	PCT	PCT/US2016 6028980	4/22/16	Pending
	<b>7003</b>				
	Methods and Compositions for the Quantitation of Mitochondrial Nucleic Acid	UT	15/268,058	9/16/16	Pending
	Methods and Compositions for the Quantitation of Mitochondrial Nucleic Acid	PCT	PCT/US2016 6052279	9/16/16	Pending
	<b>SEQ 2003</b>				
83.	Compositions and Methods for Immobilizing Nucleic Acids to Solid Supports	US_Reissue Exam	RE41,005	10/17/02	Issued
84.	Beads Bound to a Solid Support and to Nucleic Acids	US_DV	RE44,693	7/22/09	Issued
	<b>SEQ 2016</b>				
85.					
86.	Diagnostics Based on Mass Spectrometric Detection of Translated Target Polypeptides	DV	6387628	9/18/00	Issued
87.	Mass Spectrometric Detection of Polypeptides	UT	US6207370	9/2/97	Issued
88.	Mass Spectrometric Detection of Polypeptides	CP	US6322970	9/2/98	Issued
89.					
	<b>SEQ 2058</b>				
90.	Volatile Matrices for Matrix-assisted Laser Desorption/Ionization Mass Spectrometry	UT	US6104028	5/29/98	Issued
91.	Volatile Matrices for Matrix-assisted Laser Desorption/Ionization Mass Spectrometry	CT	US6265716B 1	2/29/00	Issued
	<b>SEQ 2059</b>				
92.	DNA Typing by Mass Spectrometry with Polymorphic DNA Repeat Markers	UT	US6090558	9/18/98	Issued
93.	DNA Typing by Mass Spectrometry with Polymorphic DNA Repeat Markers	DV	US6764822	4/3/00	Issued

Reference No.	PATENT OR PATENT APPLICATION TITLE	Application Type/No. Country	Patent or Publication Number	Filing Date	Status
	<b>SEQ 2069</b>				
94.	Allele-specific Sequence Variation Analysis	UT	9394565	9/2/04	Issued
	<b>SEQ 3001</b>				
95.	Target-specific Compomers and Methods of Use	UT	7785843	6/23/04	Issued
96.	Target-specific Compomers and Methods of Use	DV	7867714	6/22/09	Issued
97.	Target-specific Compomers and Methods of Use	AU	AU5327980B	6/22/05	Issued
98.	Target-specific Compomers and Methods of Use	CA	CA2569379A	6/22/05	Pending
99.	Target-specific Compomers and Methods of Use	CN	CN10142693 2B	6/22/05	Issued
100.	Target-specific Compomers and Methods of Use	ES	ES2406734	6/22/05	Pending
101.	Target-specific Compomers and Methods of Use	CH	EP1766092A 2	6/22/05	Issued
102.	Target-specific Compomers and Methods of Use	SE	EP1766092A 2	6/22/05	Issued
103.	Target-specific Compomers and Methods of Use	DE	EP1766092A 2	6/22/05	Issued
104.	Target-specific Compomers and Methods of Use	IE	EP1766092A 2	6/22/05	Issued
105.	Target-specific Compomers and Methods of Use	GB	EP1766092A 2	6/22/05	Issued
106.	Target-specific Compomers and Methods of Use	NL	EP1766092A 2	6/22/05	Issued
	<b>SEQ 6003</b>				
107.	Detection and Quantification of Biomolecules Using Mass Spectrometry	UT	US8133701	3/13/12	Issued
108.	Detection and Quantification of Biomolecules Using Mass Spectrometry	CP	US7902345	6/4/08	Issued
109.	Detection and Quantification of Biomolecules Using Mass Spectrometry	CT	US8383795	3/3/11	Issued
110.	Detection and Quantification of Biomolecules Using Mass Spectrometry	AU	AU7352560B 2	12/4/07	Issued
111.	Detection and Quantification of Biomolecules Using Mass Spectrometry	CA	CA2671864	12/4/07	Pending
112.	Detection and Quantification of Biomolecules Using Mass Spectrometry	FR	EP2099934	5/30/12	Issued
113.	Detection and Quantification of Biomolecules Using Mass Spectrometry	DE	EP2099934	5/30/12	Issued
114.	Detection and Quantification of Biomolecules Using Mass Spectrometry	UK	EP2099934	5/30/12	Issued
115.	Detection and Quantification of Biomolecules Using Mass Spectrometry	JP	5382802	12/4/07	Issued
116.	Detection and Quantification of Biomolecules Using Mass Spectrometry	CT2	US9051608	2/13/13	Issued
	<b>SEQ 6004</b>				

Reference No.	PATENT OR PATENT APPLICATION TITLE	Application Type/No. Country	Patent or Publication Number	Filing Date	Status
117.	Method for Accurate Assessment of DNA Quality After Bisulfite Treatment	US	8206927	6/26/12	Issued
118.	Method for Accurate Assessment of DNA Quality After Bisulfite Treatment	CT	8673571	5/25/12	Issued
	<b>SEQ 6009</b>				
119.					
120.	Comparative Sequence Analysis Processes and Systems	AU	AU8240143B	4/13/08	Issued
121.	Comparative Sequence Analysis Processes and Systems	CA	CA2684217A A	4/13/08	allowed
122.	Comparative Sequence Analysis Processes and Systems	DE	EP2145180B	4/13/08	Issued
123.	Comparative Sequence Analysis Processes and Systems	HK	1140264	7/14/10	Pending
124.	Comparative Sequence Analysis Processes and Systems	CN	ZL20088001 6476.7	4/13/08	Issued
125.	Comparative Sequence Analysis Processes and Systems	DV	US20130337 446	5/16/13	Pending
126.	Comparative Sequence Analysis Processes and Systems	UK	EP2145180B	4/13/08	Issued
127.	Comparative Sequence Analysis Processes and Systems	FR	EP2145180B	4/13/08	Issued
	<b>SEQ 6010</b>				
128.	Integrated Robotic Sample Transfer Device	CT	9068953	9/24/12	Issued
129.	Integrated Robotic Sample Transfer Device	CT2	14516436	10/16/14	Pending
	<b>SEQ 6044</b>				
130.					
131.	Methods and Compositions for Analyzing Nucleic Acid	UT	14402658	5/16/13	Pending
	<b>RIGAKU ACQUIRED IP</b>				
132.	High Capacity Microarray Dispensing	US	6979425	12/27/05	Issued
133.	Automated Microplate Filling Device and Method	US	6360792	3/26/02	Issued
134.	Automated Microplate Filling Device and Method	US	6148878	11/21/00	Issued

**EXHIBIT C**

**Trademarks**

<b>Mark</b>	<b>Application. No.</b>	<b>Registration No.</b>	<b>Status</b>	<b>Class(es)</b>
EpiTYPER® UNITED STATES	78/979,370	3,363,895	REGISTERED	09, 42
iPLEX® UNITED STATES	78/521,743	3,228,569	REGISTERED	01, 42
iSEQ® UNITED STATES	77/349,991	4,031,877	REGISTERED	01, 09
MassARRAY® EUROPEAN UNION	001148634	001148634	REGISTERED	42
AUSTRALIA	921937	921937	REGISTERED	09
CANADA	1151971	TMA699061	REGISTERED	09
CHINA	3249717	3249717	REGISTERED	09
EUROPEAN UNION	002807113	002807113	REGISTERED	09
HONG KONG	200402014	200402014	REGISTERED	09
JAPAN	2001025246	0004654906	REGISTERED	01,05, 09, 42
SINGAPORE	T0210355C	T0210355C	REGISTERED	09
SOUTH KOREA	4020020036407	4005729450000	REGISTERED	09
TAIWAN	091030221	01065671	REGISTERED	09
UNITED STATES	76/379,539	2,878,299	REGISTERED	09
MassExtend® JAPAN	2001025245	0004654905	REGISTERED	01
UNITED STATES	76/227,337	2,767,429	REGISTERED	01
SpectroCHIP® GERMANY	39712778.2	39712778	REGISTERED	01, 05, 09
JAPAN	2001025247	0004654907	REGISTERED	01, 05, 09, 42
UNITED STATES	75/982,140	2,602,034	REGISTERED	09
HemoCarta™ EUROPEAN UNION	12014106	12014106	REGISTERED	01, 42
Hemo ID™ CANADA	1668250		ALLOWED	01, 42
CHINA	14195855	14195855	REGISTERED	01
EUROPEAN UNION	12699484	12699484	REGISTERED	01, 42
JAPAN	2014-21085	5728939	REGISTERED	01, 42
UNITED STATES	86/069,315	4,733,377	REGISTERED	01, 42
LungCarta® AUSTRALIA	1174938	1174938	REGISTERED	01, 42
EUROPEAN UNION	12015004	12015004	REGISTERED	01, 42
UNITED STATES	85/833,886	4,633,026	REGISTERED	01, 42



<b>Mark</b>	<b>Application. No.</b>	<b>Registration No.</b>	<b>Status</b>	<b>Class(es)</b>
WIPO	1174938	1174938	REGISTERED	01, 42
LUNGFUSION	86/421,039		ALLOWED	01, 42
AGENA BIOSCIENCE				
AUSTRALIA	1244161	1244161	REGISTERED	09
CANADA	1707073		PENDING	09
CHINA	1244161	1244161	REGISTERED	09
EUROPEAN UNION	13552567	13552567	REGISTERED	09
JAPAN	1244161	1244161	REGISTERED	09
UNITED STATES	86/309,704		ALLOWED	09
WIPO	1244161	1244161	RENEWAL	09

EXHIBIT D

Mask Works

NONE.